Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -35,060 | -6,001 | -4,846 | -3,065 | -402 |
| Depreciation Amortization | 20 | 6 | 2 | -10 | N/A |
| Other Working Capital | 1,863 | -2,821 | -2,243 | -2,261 | 344 |
| Other Operating Activity | 31,109 | -109 | 1,980 | 1,953 | 38 |
| Operating Cash Flow | $-2,068 | $-8,926 | $-5,108 | $-3,381 | $-20 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 500 | -2,000 | N/A | N/A | N/A |
| PPE Investments | -9 | -57 | -36 | -13 | N/A |
| Other Investing Activity | 0 | -8,003 | 0 | 0 | 0 |
| Investing Cash Flow | $491 | $-10,060 | $-36 | $-13 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 995 | 10,250 | 250 | 250 | 250 |
| Common Stock Issued | N/A | 11,630 | 11,953 | 11,953 | N/A |
| Other Financing Activity | -75 | -1,261 | -76 | -76 | 17 |
| Financing Cash Flow | $920 | $20,619 | $12,127 | $12,127 | $267 |
| Beginning Cash Position | 9,637 | 8,004 | 4 | 4 | 4 |
| End Cash Position | 8,980 | 9,637 | 6,987 | 8,735 | 250 |
| Net Cash Flow | $-657 | $1,633 | $6,983 | $8,732 | $247 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,068 | -8,926 | -5,108 | -3,381 | -20 |
| Capital Expenditure | -9 | -57 | -36 | -13 | N/A |
| Free Cash Flow | -2,077 | -8,983 | -5,144 | -3,395 | -20 |